Drugs / Piperacillin/tazobactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03376529 | Nov → Dec 2017 | — | Spero Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperacillin/tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03376529 ↗ |
| Route | Intravenous | “piperacillin/tazobactam 4.5 grams IV over 1 hour” NCT03376529 ↗ |